Your browser is no longer supported. Please, upgrade your browser.
ASNS Arsanis, Inc. daily Stock Chart
Arsanis, Inc.
Index- P/E- EPS (ttm)-2.05 Insider Own20.80% Shs Outstand14.29M Perf Week33.67%
Market Cap343.82M Forward P/E- EPS next Y-7.54 Insider Trans- Shs Float11.41M Perf Month94.96%
Income-28.10M PEG- EPS next Q-0.77 Inst Own74.60% Short Float0.39% Perf Quarter121.34%
Sales- P/S- EPS this Y-73.80% Inst Trans- Short Ratio1.72 Perf Half Y-
Book/sh-154.21 P/B- EPS next Y-0.50% ROA- Target Price25.00 Perf Year-
Cash/sh1.84 P/C13.07 EPS next 5Y- ROE- 52W Range10.40 - 28.69 Perf YTD88.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.15% Beta-
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low131.35% ATR2.23
Employees39 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)79.73 Volatility20.18% 11.39%
OptionableNo Debt/Eq- EPS Q/Q-29.10% Profit Margin- Rel Volume21.37 Prev Close25.43
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume25.92K Price24.06
Recom1.70 SMA2043.47% SMA5063.76% SMA20066.85% Volume553,692 Change-5.39%
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.47%
Mar-14-18 08:00AM  Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies Business Wire +5.98%
Mar-09-18 07:00AM  Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Business Wire
Mar-05-18 08:00AM  Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference Business Wire
Dec-29-17 04:25PM  What You Must Know About Arsanis Incs (NASDAQ:ASNS) ROE Simply Wall St.
Nov-20-17 04:10PM  Arsanis Announces Closing of Initial Public Offering Business Wire
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.